Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MEDI2228 |
Synonyms | |
Therapy Description |
MEDI2228 is an antibody-drug conjugate comprising a BCMA targeted antibody linked to a pyrrolobenzodiazepine dimer, which delivers the DNA cross-linking agent to BCMA-expressing tumor cells, potentially resulting in decreased tumor growth (Blood (2017) 130 (Supplement 1): 3153, PMID: 32060401). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MEDI2228 | MEDI-2228|anti-BCMA ADC MEDI2228|Anti-BCMA/PBD MEDI2228 | TNFRSF17 Antibody 20 | MEDI2228 is an antibody-drug conjugate comprising a BCMA targeted antibody linked to a pyrrolobenzodiazepine dimer, which delivers the DNA cross-linking agent to BCMA-expressing tumor cells, potentially resulting in decreased tumor growth (Blood (2017) 130 (Supplement 1): 3153, PMID: 32060401). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03489525 | Phase I | MEDI2228 | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228) | Completed | USA | GRC | ESP | AUS | 0 |